Innovent Biologics, Inc. (FRA:6IB)
Germany
· Delayed Price · Currency is EUR 9.95
-0.25 (-2.45%)
At close: Dec 5, 2025
Innovent Biologics Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2016 |
| Cash & Equivalents | 9,540 | 7,508 | 10,052 | 9,163 | 8,377 | 7,764 | Upgrade
|
| Short-Term Investments | - | 375.56 | 867.53 | - | - | - | Upgrade
|
| Trading Asset Securities | - | - | 50 | 3.21 | 638.21 | 357.3 | Upgrade
|
| Cash & Short-Term Investments | 9,540 | 7,884 | 10,970 | 9,166 | 9,015 | 8,121 | Upgrade
|
| Cash Growth | 10.56% | -28.13% | 19.68% | 1.67% | 11.01% | 72.97% | Upgrade
|
| Accounts Receivable | 1,722 | 1,184 | 1,006 | 575.27 | 968.41 | 475.38 | Upgrade
|
| Other Receivables | - | - | - | - | - | 91.72 | Upgrade
|
| Receivables | 1,722 | 1,184 | 1,006 | 575.27 | 975.91 | 575.2 | Upgrade
|
| Inventory | 1,128 | 822.17 | 968.09 | 1,429 | 1,347 | 705.66 | Upgrade
|
| Other Current Assets | 702.27 | 382.52 | 484.38 | 336.52 | 212.4 | 64.69 | Upgrade
|
| Total Current Assets | 13,093 | 10,273 | 13,428 | 11,507 | 11,551 | 9,467 | Upgrade
|
| Property, Plant & Equipment | 5,602 | 5,647 | 4,656 | 3,826 | 3,090 | 1,911 | Upgrade
|
| Long-Term Investments | 3,132 | 3,901 | 794.09 | 630.2 | 417.26 | 12.94 | Upgrade
|
| Other Intangible Assets | 1,388 | 307.48 | 27.79 | 30.05 | 19.75 | - | Upgrade
|
| Long-Term Deferred Charges | - | 975.12 | 1,242 | 1,168 | 752.45 | 32.63 | Upgrade
|
| Other Long-Term Assets | 379.25 | 499.02 | 478.64 | 427.63 | 412.07 | 410.15 | Upgrade
|
| Total Assets | 23,594 | 21,603 | 20,627 | 17,589 | 16,244 | 11,835 | Upgrade
|
| Accounts Payable | 432.29 | 357.68 | 372.55 | 325.62 | 195.05 | 120.62 | Upgrade
|
| Accrued Expenses | 2,595 | 2,739 | 1,962 | 1,517 | 1,678 | 819.95 | Upgrade
|
| Current Portion of Long-Term Debt | 1,109 | 405.1 | 1,195 | 888 | 365 | 255 | Upgrade
|
| Current Portion of Leases | 6.09 | 8.83 | 25.18 | 26.39 | 22.27 | 16.16 | Upgrade
|
| Current Income Taxes Payable | 150.27 | 75.84 | 194.05 | 3.3 | 60.59 | - | Upgrade
|
| Current Unearned Revenue | 226.97 | 256.41 | 416.17 | 434.91 | 355.51 | 120.44 | Upgrade
|
| Other Current Liabilities | 493.21 | 525.53 | 312.16 | 303.71 | 374.05 | 153.69 | Upgrade
|
| Total Current Liabilities | 5,012 | 4,369 | 4,477 | 3,499 | 3,050 | 1,486 | Upgrade
|
| Long-Term Debt | 2,263 | 2,412 | 2,327 | 2,215 | 2,023 | 925.18 | Upgrade
|
| Long-Term Leases | 1.61 | 4.76 | 73.42 | 98.68 | 86.39 | 10.23 | Upgrade
|
| Long-Term Unearned Revenue | 1,232 | 1,215 | 960.05 | 883.28 | 753.27 | 633.96 | Upgrade
|
| Other Long-Term Liabilities | 663.13 | 483.82 | 262.71 | 162.31 | 0.34 | - | Upgrade
|
| Total Liabilities | 9,172 | 8,485 | 8,100 | 6,859 | 5,913 | 3,055 | Upgrade
|
| Common Stock | 0.11 | 0.11 | 0.11 | 0.11 | 0.1 | 0.1 | Upgrade
|
| Additional Paid-In Capital | 28,189 | 27,723 | 27,324 | 24,706 | 22,494 | 18,541 | Upgrade
|
| Retained Earnings | -15,072 | -15,906 | -15,768 | -14,740 | -12,560 | -9,982 | Upgrade
|
| Comprehensive Income & Other | 1,305 | 1,301 | 970.54 | 763.86 | 397.02 | 220.41 | Upgrade
|
| Total Common Equity | 14,422 | 13,118 | 12,528 | 10,730 | 10,330 | 8,780 | Upgrade
|
| Shareholders' Equity | 14,422 | 13,118 | 12,528 | 10,730 | 10,330 | 8,780 | Upgrade
|
| Total Liabilities & Equity | 23,594 | 21,603 | 20,627 | 17,589 | 16,244 | 11,835 | Upgrade
|
| Total Debt | 3,379 | 2,831 | 3,621 | 3,229 | 2,497 | 1,207 | Upgrade
|
| Net Cash (Debt) | 6,161 | 5,053 | 7,349 | 5,938 | 6,518 | 6,915 | Upgrade
|
| Net Cash Growth | 16.68% | -31.25% | 23.77% | -8.91% | -5.73% | 80.53% | Upgrade
|
| Net Cash Per Share | 3.70 | 3.10 | 4.71 | 3.98 | 4.48 | 5.10 | Upgrade
|
| Filing Date Shares Outstanding | 1,654 | 1,638 | 1,622 | 1,534 | 1,462 | 1,403 | Upgrade
|
| Total Common Shares Outstanding | 1,654 | 1,638 | 1,622 | 1,534 | 1,462 | 1,403 | Upgrade
|
| Working Capital | 8,080 | 5,904 | 8,951 | 8,008 | 8,501 | 7,981 | Upgrade
|
| Book Value Per Share | 8.72 | 8.01 | 7.72 | 6.99 | 7.07 | 6.26 | Upgrade
|
| Tangible Book Value | 13,033 | 12,810 | 12,500 | 10,700 | 10,311 | 8,780 | Upgrade
|
| Tangible Book Value Per Share | 7.88 | 7.82 | 7.71 | 6.97 | 7.05 | 6.26 | Upgrade
|
| Buildings | - | 1,702 | 402.67 | 402.46 | 389.73 | 389.73 | Upgrade
|
| Machinery | - | 3,133 | 4,795 | 2,523 | 1,420 | 1,183 | Upgrade
|
| Construction In Progress | - | 1,339 | 6.18 | 1,139 | 1,293 | 287.66 | Upgrade
|
| Leasehold Improvements | - | 426.63 | 121.82 | 107.66 | 106.85 | 76.76 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.